|
1
|
Beis-Filho J, Gobbi H and Peed AM: WHO
Classification of Tumours Editorial Board Breast Tumours.
International Agency for Research on Cancer. Metaplastic Carcinoma;
Lyon: pp. 134–138. 2019
|
|
2
|
Koenig C and Tavassoli FA: Mucinous
cystadenocarcinoma of the breast. Am J Surg Pathol. 22:698–703.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petersson F, Pang B, Thamboo TP and Putti
TC: Mucinous cystadenocarcinoma of the breast with amplification of
the HER2-gene confirmed by FISH: The first case reported. Hum
Pathol. 41:910–913. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kucukzeybek BB, Yigit S, Sari AA, Rezanko
T, Durak E and Sadullahoglu C: Primary mucinous cystadenocarcinoma
of the breast with amplification of the HER2 gene confirmed by
FISH-case report and review of the literature. Pol J Pathol.
65:70–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seong M, Ko EY, Han BK, Cho SY, Cho EY,
Lee SK and Lee JE: Radiologic findings of primary mucinous
cystadenocarcinoma of the breast: A report of two cases and a
literature review. J Breast Cancer. 19:330–333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaur K, Shah A, Gandhi J and Trivedi P:
Mucinous cystadenocarcinoma of the breast: A new entity with broad
differentials-A case report. J Egypt NatI Cancer Inst. 34:92022.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guzelis I, Kucukzeybek BB, Uyaroglu MA,
Gokova MB, Sezgin G and Kucukzeybek Y: HER2-positive mucinous
cystadenocarcinoma of the breast coexisting with invasive lobular
carcinoma: A case report and review of the literature. Diagn
Cytopathol. 52:E208–E214. 2024. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sickles E, D'Orsi CJ, Bassett LW, Appleton
CM, Berg WA, Burnside ES, Feig SA, Gavenonis SC, Newell MS and
Trinh MM: ACR BI-RADS® Mammography. ACR
BI-RADS® Atlas, Breast Imaging Reporting and Data
System. American College of Radiology; Reston, VA: 2013
|
|
9
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; New York, NY: 2010
|
|
10
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Breast cancer version 2.2015. J Natl Comp Canc
Netw. 13:448–475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin LH, Hernandez O, Zhu K, Guth A, Cotzia
P and Darvishian F: Genetic profile of primary mucinous
cystadenocarcinoma of the breast-A case report. Breast J.
27:731–734. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lei T, Shi YQ and Chen TB: Mammary
mucinous cystadenocarcinoma with long-term follow-up: Molecular
information and literature review. Diagn Pathol. 18:132023.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Geyer FC, Pareja F, Weigelt B, Rakha E,
Ellis IO, Schnitt SJ and Reis-Filho JS: The spectrum of
triple-negative breast disease: High- and low-grade lesions. Am J
Pathol. 187:2139–2151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen WY, Hu YH, Tsai YH, Hang JF, Tan PH
and Che CJ: Mucinous cystadenocarcinoma of the breast harbours
TRPS1 expressions and PIK3CA alterations. Histopathology.
84:550–555. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao X, Luo Y, Shen S and Ren X: Primary
mucinous cystadenocarcinoma of the breast: A case report and
literature review. Oncol Lett. 29:602024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Budzik MP: Primary breast mucinous
cystadenocarcinoma-histopathological analysis. Transl Cancer Res.
12:230–232. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ferrari A, Vincent-Salomon A, Pivot X,
Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I,
MacGrogan G, et al: A whole-genome sequence and transcriptome
perspective on HER2-positive breast cancers. Nat Commun.
7:122222016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lesurf R, Griffith OL, Griffith M, Hundal
J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, et al:
Genomic characterization of HER2-positive breast cancer and
response to neoadjuvant trastuzumab and chemotherapy-results from
the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 28:1070–1077. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lui GYL, Grandori C and Kemp CJ: CDK12: An
emerging therapeutic target for cancer. J Clin Pathol. 71:957–962.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bivin WW, Yergiyev O, Bunker ML, Silverman
JF and Krishnamurti U: GRB7 expression and correlation with HER2
amplification in invasive breast carcinoma. Appl Immunohistochem
Mol Morphol. 25:553–558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng HC, Xiang LW, Cui ZG, Xue H, Ying E
and Zhao MZ: The clinicopathological and prognostic significances
of LATS1 expression in breast cancer. Histol Histopathol.
37:665–677. 2022.PubMed/NCBI
|
|
22
|
Wang R, Liang L, Matsumoto M, Iwata K,
Umemura A and He F: Reactive oxygen species and NRF2 signaling,
friends or foes in cancer? Biomolecules. 13:3532023. View Article : Google Scholar : PubMed/NCBI
|
